Humacyte, Inc. (NASDAQ:HUMA) Stock Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 10.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 721,318 shares of the company’s stock after acquiring an additional 66,946 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.60% of Humacyte worth $3,924,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HUMA. Millennium Management LLC lifted its holdings in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares during the period. Renaissance Technologies LLC lifted its holdings in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the last quarter. Marshall Wace LLP lifted its holdings in Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after acquiring an additional 450,031 shares during the last quarter. Private Advisor Group LLC boosted its position in shares of Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after purchasing an additional 6,510 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $1,550,000. 44.71% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is currently owned by insiders.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $4.10 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market capitalization of $516.02 million, a P/E ratio of -3.06 and a beta of 1.38. The business has a 50-day moving average of $4.99 and a two-hundred day moving average of $5.98. Humacyte, Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $9.97.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HUMA. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Humacyte in a research report on Wednesday, November 13th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $13.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.